<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576066</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-H0731-201</org_study_id>
    <nct_id>NCT03576066</nct_id>
  </id_info>
  <brief_title>A Study Evaluating ABI-H0731 as Adjunctive Therapy in Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if ABI-H0731 given in combination with a standard
      of care HBV medication is safe and effective in patients with chronic hepatitis B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731
      as Adjunctive Therapy in Virally-suppressed Patients with Chronic Hepatitis B
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Actual">July 5, 2019</completion_date>
  <primary_completion_date type="Actual">July 5, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean log10 serum viral antigen (HBsAg or HBeAg) from Baseline (Day 1) to Week 24 on ABI-H0731 + SOC NUC as compared to placebo + SOC NUC</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events, premature discontinuations, abnormal safety laboratory results, electrocardiogram (ECG), or vital signs</measure>
    <time_frame>Up to Follow-up (maximum up to Week 36)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with abnormal alanine aminotransferase (ALT) at Baseline who have normal ALT at Week 24 on ABI-H0731 + NUC therapy as compared with placebo + NUC therapy</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough levels of ABI-H0731 on ABI-H0731 + SOC NUC therapy</measure>
    <time_frame>Baseline, Weeks 2, 4, 12, 24, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough to peak ratios of ABI-H0731 on ABI-H0731 + SOC NUC therapy</measure>
    <time_frame>Baseline, Weeks 2, 4, 12, 24, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough levels of SOC NUC on ABI-H0731 + SOC NUC therapy as compared with placebo + SOC NUC therapy</measure>
    <time_frame>Baseline, Weeks 2, 4, 12, 24, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough to peak ratios of SOC NUC on ABI-H0731 + SOC NUC therapy as compared with placebo + SOC NUC therapy</measure>
    <time_frame>Baseline, Weeks 2, 4, 12, 24, and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>ABI-H0731 &amp; SOC NUC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virologically suppressed participants will receive ABI-H0731 along with SOC NUC (ETV, TDF or TAF) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; SOC NUC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Virologically suppressed participants will receive matching placebo tablets and continue their SOC NUC (ETV, TDF or TAF) for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-H0731</intervention_name>
    <description>Participants will receive 300 mg QD ABI-H0731 tablets orally.</description>
    <arm_group_label>ABI-H0731 &amp; SOC NUC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC NUC</intervention_name>
    <description>Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally (QD frequency) as per approved package insert.</description>
    <arm_group_label>ABI-H0731 &amp; SOC NUC</arm_group_label>
    <other_name>ETV</other_name>
    <other_name>TDF</other_name>
    <other_name>TAF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Participants will receive matching QD placebo tablets orally.</description>
    <arm_group_label>Placebo &amp; SOC NUC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC NUC</intervention_name>
    <description>Participants will receive SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.</description>
    <arm_group_label>Placebo &amp; SOC NUC</arm_group_label>
    <other_name>ETV</other_name>
    <other_name>TDF</other_name>
    <other_name>TAF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female between ages 18 and 70 years

          -  Virologically-suppressed (defined as HBV DNA ≤LOQ) for at least 6 months before
             screening on SOC NUC therapy

          -  HBeAg-positive or HBeAg-negative at screening

          -  In good general health except for chronic HBV infection

        Key Exclusion Criteria:

          -  Co-infection with HIV, HCV, HEV or HDV

          -  History or evidence of hepatic decompensation (including gastrointestinal bleeding or
             esophageal varices) at any time prior to or at time of screening

          -  Clinically significant cardiac or pulmonary disease, chronic or recurrent renal or
             urinary tract disease, liver disease other than HBV, endocrine disorder, autoimmune
             disorder, diabetes mellitus requiring treatment with insulin or hypoglycemic agents,
             neuromuscular, musculoskeletal, or mucocutaneous conditions requiring frequent
             treatment, seizure disorders requiring treatment, or other medical conditions
             requiring frequent medical management or pharmacologic or surgical treatment that in
             the opinion of the Investigator or the Sponsor makes the subject unsuitable for the
             study

          -  Previous treatment with an investigational agent for HBV other than ABI-H0731 in the
             last 6 months before screening

          -  History of HCC

          -  Females who are lactating or pregnant or wish to become pregnant are excluded from the
             study

          -  Exclusionary laboratory parameters at screening include:

               -  Platelet count &lt;100,000/mm3

               -  Albumin &lt;lower limit of normal (LLN)

               -  Direct bilirubin &gt;1.2×ULN

               -  ALT &gt;5×ULN at screening

               -  International Normalized Ratio (INR) &gt;1.5×ULN

               -  Glomerular filtration rate (GFR) &lt;60 mL/min/1.73 m2 by CKD-EPI equation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asia Pacific Liver Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research and Education</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Research Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Care</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sing Chan, MD</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiaoli Ma, MD</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Center</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Research Institute</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <disposition_first_submitted>June 3, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>June 3, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 5, 2020</disposition_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHB</keyword>
  <keyword>HBV</keyword>
  <keyword>HBeAg-positive</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>HBeAg-negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

